デフォルト表紙
市場調査レポート
商品コード
1328016

ePRO、電子患者日誌、eCOAの世界市場

ePRO, E-Patient Diaries and eCOA

出版日: | 発行: Global Industry Analysts, Inc. | ページ情報: 英文 360 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=151.55円
ePRO、電子患者日誌、eCOAの世界市場
出版日: 2023年08月14日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 360 Pages
納期: 即日から翌営業日
● ご注意事項
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

ePRO、電子患者日誌、eCOAの世界市場は2030年までに48億米ドルに達する

COVID-19後のビジネス環境が変化する中、2022年に16億米ドルと推定されたePRO、電子患者日誌、eCOAの世界市場は、2030年には48億米ドルに達すると予測され、分析期間2022-2030年のCAGRは15%で成長すると予測されます。現在進行中のパンデミック後の回復を考慮し、本レポートで分析されているセグメントの一つであるeCOA分野は15.3% のCAGRで成長し、予測期間終了までに15億米ドルに達すると予測されています。現在進行中のパンデミック後の回復を考慮し、ePRO分野の今後8年間のCAGRを16.4%に修正しました。

米国市場は5億6,140万米ドル、中国はCAGR 17.9%で成長すると予測

米国のePRO、電子患者日誌、eCOA市場は、2022年には5億6,140万米ドルになると推定されます。世界第2位の経済大国である中国は、2022年から2030年までの分析期間において17.9%のCAGRで推移し、2030年までに6億2,080万米ドルの市場規模に達すると予測されています。その他の注目すべき地理的市場としては、日本とカナダがあり、2022年から2030年にかけてそれぞれ12.4%と14.2%の成長が予測されています。欧州では、ドイツがCAGR約13.3%で成長すると予測されています。

調査対象企業の例

  • Dassault Systemes SE(3DS)
  • Almac Group
  • Clinical Ink, Inc.
  • Criterium, Inc.
  • Dacima Software, Inc.
  • Anju Software
  • ArisGlobal LLC
  • Cogstate Ltd.
  • Cambridge Cognition Ltd.
  • CliniOps Inc.,
  • Castor EDC
  • ClinCapture
  • Clinion
  • Adelphi Group
  • Crucial Data Solutions

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • 世界のその他の地域

第4章 競合

目次
Product Code: MCP11846

What`s New for 2023?

»Special coverage on Russia-Ukraine war; global inflation; easing of "zero-Covid" policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.

»Global competitiveness and key competitor percentage market shares

» Market presence across multiple geographies - Strong/Active/Niche/Trivial

»Online interactive peer-to-peer collaborative bespoke updates

»Access to our digital archives and MarketGlass Research Platform

»Complimentary updates for one year

Looking Ahead to 2023

The global economy is at a critical crossroads with a number of interlocking challenges and crises running in parallel. The uncertainty around how Russia`s war on Ukraine will play out this year and the war`s role in creating global instability means that the trouble on the inflation front is not over yet. Food and fuel inflation will remain a persistent economic problem. Higher retail inflation will impact consumer confidence and spending. As governments combat inflation by raising interest rates, new job creation will slowdown and impact economic activity and growth. Lower capital expenditure is in the offing as companies go slow on investments, held back by inflation worries and weaker demand. With slower growth and high inflation, developed markets seem primed to enter into a recession. Fears of new COVID outbreaks and China's already uncertain post-pandemic path poses a real risk of the world experiencing more acute supply chain pain and manufacturing disruptions this year. Volatile financial markets, growing trade tensions, stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced. Year 2023 is expected to be tough year for most markets, investors and consumers. Nevertheless, there is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.

Global ePRO, E-Patient Diaries and eCOA Market to Reach $4.8 Billion by 2030

In the changed post COVID-19 business landscape, the global market for ePRO, E-Patient Diaries and eCOA estimated at US$1.6 Billion in the year 2022, is projected to reach a revised size of US$4.8 Billion by 2030, growing at a CAGR of 15% over the analysis period 2022-2030. eClinical Outcome Assessments (eCOAs), one of the segments analyzed in the report, is projected to record a 15.3% CAGR and reach US$1.5 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Epatient Reported Outcomes (epros) segment is readjusted to a revised 16.4% CAGR for the next 8-year period.

The U.S. Market is Estimated at $561.4 Million, While China is Forecast to Grow at 17.9% CAGR

The ePRO, E-Patient Diaries and eCOA market in the U.S. is estimated at US$561.4 Million in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$620.8 Million by the year 2030 trailing a CAGR of 17.9% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 12.4% and 14.2% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 13.3% CAGR.

Select Competitors (Total 75 Featured) -

  • Dassault Systemes SE (3DS)
  • Almac Group
  • Clinical Ink, Inc.
  • Criterium, Inc.
  • Dacima Software, Inc.
  • Anju Software
  • ArisGlobal LLC
  • Cogstate Ltd.
  • Cambridge Cognition Ltd.
  • CliniOps Inc.,
  • Castor EDC
  • ClinCapture
  • Clinion
  • Adelphi Group
  • Crucial Data Solutions

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Impact of COVID-19 Pandemic and Looming Global Recession
    • Year 2021 in Review and Near-term Outlook
    • Prolonged Pandemic, Ukraine-Russia Conflict and Ensuing Economic Disruptions Impact Growth Outlook
    • World Economic Growth Projections (Real GDP, Annual % Change) for the Years 2021, 2022 and 2023
    • Pandemic Jolt Brings Strategic & Lasting Changes to Healthcare Sector
    • COVID-19 Expedites Healthcare Ecosystem's Evolution for Better Care & Cost Savings
    • The Adoption of Telemedicine Services Accelerates Amidst the Pandemic
    • Telemedicine Leads Digital Health Investments Driven by COVID-19: Leading Categories of Digital Health by Funding (In US$ Million) for the Year 2020
    • Telehealth Visits in the US (In Million) for the Year 2020
    • Global Number of Telemedicine Patients (In Million) for the Years 2016, 2018, 2020, 2023 & 2025
    • Pandemic Impact on eCOA, ePRO Market
    • COVID-19 Outbreak Compels Clinical Trials Industry to Move Towards ePRO
    • eCOA Solutions Help Address Hurdles Due to COVID-19 Pandemic
    • eCOA Playing a Part in Development of COVID-19 Vaccine
    • An Introduction to ePRO, E-Patient Diaries and eCOA
    • Global Market Prospects & Outlook
    • eCOA: The Largest Category
    • Competition
    • ePRO, E-Patient Diaries and eCOA - Global Key Competitors Percentage Market Share in 2022 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
    • Recent Market Activity
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Digitalization of Healthcare Services and Rising Importance of Electronic Data Capture Technologies to Fuel Market Growth
    • Global Digital Health Market: Annual Revenues in US$ Million by Region/Country for 2020 and 2027
    • Growing Demand for Clinical Trials Drives Need for ePRO, ePatient Diaries, and eCOA Solutions
    • Industry-Funded, Interventional Clinical Trial Study Starts for the Period 2015-2022E
    • Clinical Trials in the US: % Change in Trial Starts by Therapy Area for 2020 Vs 2019
    • Breakdown of Trial Starts by Therapeutic Area (2021)
    • COVID-19 Pandemic Triggers Technology Adoption in Clinical Trials
    • Global Venture Funding (in $ Million) in Digital Health Solutions Targeting Clinical Trials for 2015-2020
    • Trends in Clinical Trials to Influence Market Demand
    • Clinical Trials Increasingly Embraced Technology Amid COVID-19 Pandemic
    • Shift Towards Decentralized/Virtual Clinical Trials to Boost Market Prospects
    • Global Virtual Clinical Trials Market Size (in US$ Billion) for the Years 2020, 2022, 2024 and 2026
    • Global Virtual Clinical Trials Market by Indication (in %) for 2022E
    • Decentralized Clinical Trials Driving Greater Demand for Patient-Centric Drug Development
    • Role of eCOA & ePRO in Enhancing Data Accuracy of Decentralized Clinical Trials
    • Growing Volumes of Data Generation in Decentralized Trials: A Challenge
    • Adoption of Digital Technologies in Contract Research Organizations Bodes Well for the Market
    • Global Contract Research Outsourcing Market Revenues (US$ Million) by Geographic Region for 2020 and 2027
    • Pharmaceutical R&D Spending Worldwide (USD Billion): 2015-2025
    • COVID-19 and Implications for Drug Development Regulations & Processes
    • Advances in ePRO Technologies Promise Better Clinical Decision Making in Healthcare Systems
    • Rise in Telemedicine Services Present Market Opportunities
    • Global Tele-Healthcare Market (In US$ Million) for Years 2020, 2022, 2024 and 2026
    • Growing Adoption of Mobile Technologies and BYOD Trend in Healthcare Industry Boosts Market Prospects
    • Smartphone Adoption Rate as Share of Total Population: 2016-2021
    • Mobile Device Use in Healthcare Settings: % Usage by Type of Mobile Device
    • Electronic Patient Record (ePRO) Solutions Emerge as Ideal Replacements for Paper-Based PRO systems
    • Major Benefits of ePRO over Paper Form in Clinical Trials
    • Delivering Better Data: A Key Benefit of ePRO
    • Factors Ensuring Success ePRO Implementations
    • ePatient-Reported Outcomes (PROs) Gain Importance in Oncology Studies
    • Key Technology Trends Impacting the ePRO in Clinical Trials
    • Data Integrity, Security & Privacy: Key Priorities for ePRO Solutions
    • Integrating AI Into ePRO Improves the Efficiency of ePRO Data Collection and Assessment
    • Electronic Clinical Outcome Assessment Solution (eCOA) Market: Poised for Growth
    • Global e-COA Market by Delivery Mode (in %) for 2022E
    • eCOA Usage by Clinical Trial Phase (in %) for 2021
    • Technological Trends Transforming eCOA Solutions Market
    • Future Trends in eCOA Market: A Review
    • eCOA Proves Beneficial in Addressing Clinical Trial Challenges During COVID-19 Pandemic
    • UAT, Challenges and Embedded UAT for eCOAs
    • Benefits of BYOD for eCOAs
    • E-Patient Diaries: Significant Advantages over Paper Diaries to Drive Market
    • Major Benefits of ePatient Diary
    • Increase in Healthcare Spending to Propel Demand
    • World Healthcare Expenditure (In US$ Billion) for the Years 2017-2023
    • Spending as % of GDP by Country for 2019 and 2030
    • Increasing Burden of Chronic Diseases and Focus on Drug Development, Therapies and Vaccines Boosts Market
    • Global Cancer Incidence: Number of New Cancer Cases in Million for the Years 2018, 2020, 2025, 2030, 2035 and 2040
    • Global Annual Medical Cost of CVD in US$ Billion (2010-2030)
    • Fatalities by Heart Conditions: Estimated Percentage Breakdown for Cardiovascular Disease, Ischemic Heart Disease, Stroke, and Others
    • World Diabetes and Population Statistics (2019, 2030 & 2045)
    • Aging World Population & COVID-19 Induced Re-Focus on Aging-In-Place to Drive Market Growth
    • Global Aging Population Statistics for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2035 and 2050
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World ePRO, E-Patient Diaries and eCOA Market Analysis of Annual Sales in US$ Thousand for Years 2020 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for ePRO, E-Patient Diaries and eCOA by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 3: World 8-Year Perspective for ePRO, E-Patient Diaries and eCOA by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2023 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for eClinical Outcome Assessments (eCOAs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 5: World 8-Year Perspective for eClinical Outcome Assessments (eCOAs) by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
    • TABLE 6: World Recent Past, Current & Future Analysis for ePatient Reported Outcomes (ePROs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 7: World 8-Year Perspective for ePatient Reported Outcomes (ePROs) by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Clinician Reported Outcomes (ClinROs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 9: World 8-Year Perspective for Clinician Reported Outcomes (ClinROs) by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for ePatient Diaries by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 11: World 8-Year Perspective for ePatient Diaries by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
    • TABLE 12: World Recent Past, Current & Future Analysis for Performance Outcomes (PerfOs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 13: World 8-Year Perspective for Performance Outcomes (PerfOs) by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Observer Reported Outcomes (ObsROs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 15: World 8-Year Perspective for Observer Reported Outcomes (ObsROs) by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Clinical Trial Sponsors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 17: World 8-Year Perspective for Clinical Trial Sponsors by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
    • TABLE 18: World Recent Past, Current & Future Analysis for Contract Research Organizations (CROs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 19: World 8-Year Perspective for Contract Research Organizations (CROs) by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 21: World 8-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Academic Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 23: World 8-Year Perspective for Academic Institutes by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
    • TABLE 24: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 25: World 8-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • ePRO, E-Patient Diaries and eCOA Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
    • TABLE 26: USA Recent Past, Current & Future Analysis for ePRO, E-Patient Diaries and eCOA by Solution Type - eClinical Outcome Assessments (eCOAs), ePatient Reported Outcomes (ePROs), Clinician Reported Outcomes (ClinROs), ePatient Diaries, Performance Outcomes (PerfOs) and Observer Reported Outcomes (ObsROs) - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 27: USA 8-Year Perspective for ePRO, E-Patient Diaries and eCOA by Solution Type - Percentage Breakdown of Value Revenues for eClinical Outcome Assessments (eCOAs), ePatient Reported Outcomes (ePROs), Clinician Reported Outcomes (ClinROs), ePatient Diaries, Performance Outcomes (PerfOs) and Observer Reported Outcomes (ObsROs) for the Years 2023 & 2030
    • TABLE 28: USA Recent Past, Current & Future Analysis for ePRO, E-Patient Diaries and eCOA by End-Use - Clinical Trial Sponsors, Contract Research Organizations (CROs), Hospitals, Academic Institutes and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 29: USA 8-Year Perspective for ePRO, E-Patient Diaries and eCOA by End-Use - Percentage Breakdown of Value Revenues for Clinical Trial Sponsors, Contract Research Organizations (CROs), Hospitals, Academic Institutes and Other End-Uses for the Years 2023 & 2030
  • CANADA
    • TABLE 30: Canada Recent Past, Current & Future Analysis for ePRO, E-Patient Diaries and eCOA by Solution Type - eClinical Outcome Assessments (eCOAs), ePatient Reported Outcomes (ePROs), Clinician Reported Outcomes (ClinROs), ePatient Diaries, Performance Outcomes (PerfOs) and Observer Reported Outcomes (ObsROs) - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 31: Canada 8-Year Perspective for ePRO, E-Patient Diaries and eCOA by Solution Type - Percentage Breakdown of Value Revenues for eClinical Outcome Assessments (eCOAs), ePatient Reported Outcomes (ePROs), Clinician Reported Outcomes (ClinROs), ePatient Diaries, Performance Outcomes (PerfOs) and Observer Reported Outcomes (ObsROs) for the Years 2023 & 2030
    • TABLE 32: Canada Recent Past, Current & Future Analysis for ePRO, E-Patient Diaries and eCOA by End-Use - Clinical Trial Sponsors, Contract Research Organizations (CROs), Hospitals, Academic Institutes and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 33: Canada 8-Year Perspective for ePRO, E-Patient Diaries and eCOA by End-Use - Percentage Breakdown of Value Revenues for Clinical Trial Sponsors, Contract Research Organizations (CROs), Hospitals, Academic Institutes and Other End-Uses for the Years 2023 & 2030
  • JAPAN
    • TABLE 34: Japan Recent Past, Current & Future Analysis for ePRO, E-Patient Diaries and eCOA by Solution Type - eClinical Outcome Assessments (eCOAs), ePatient Reported Outcomes (ePROs), Clinician Reported Outcomes (ClinROs), ePatient Diaries, Performance Outcomes (PerfOs) and Observer Reported Outcomes (ObsROs) - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 35: Japan 8-Year Perspective for ePRO, E-Patient Diaries and eCOA by Solution Type - Percentage Breakdown of Value Revenues for eClinical Outcome Assessments (eCOAs), ePatient Reported Outcomes (ePROs), Clinician Reported Outcomes (ClinROs), ePatient Diaries, Performance Outcomes (PerfOs) and Observer Reported Outcomes (ObsROs) for the Years 2023 & 2030
    • TABLE 36: Japan Recent Past, Current & Future Analysis for ePRO, E-Patient Diaries and eCOA by End-Use - Clinical Trial Sponsors, Contract Research Organizations (CROs), Hospitals, Academic Institutes and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 37: Japan 8-Year Perspective for ePRO, E-Patient Diaries and eCOA by End-Use - Percentage Breakdown of Value Revenues for Clinical Trial Sponsors, Contract Research Organizations (CROs), Hospitals, Academic Institutes and Other End-Uses for the Years 2023 & 2030
  • CHINA
    • TABLE 38: China Recent Past, Current & Future Analysis for ePRO, E-Patient Diaries and eCOA by Solution Type - eClinical Outcome Assessments (eCOAs), ePatient Reported Outcomes (ePROs), Clinician Reported Outcomes (ClinROs), ePatient Diaries, Performance Outcomes (PerfOs) and Observer Reported Outcomes (ObsROs) - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 39: China 8-Year Perspective for ePRO, E-Patient Diaries and eCOA by Solution Type - Percentage Breakdown of Value Revenues for eClinical Outcome Assessments (eCOAs), ePatient Reported Outcomes (ePROs), Clinician Reported Outcomes (ClinROs), ePatient Diaries, Performance Outcomes (PerfOs) and Observer Reported Outcomes (ObsROs) for the Years 2023 & 2030
    • TABLE 40: China Recent Past, Current & Future Analysis for ePRO, E-Patient Diaries and eCOA by End-Use - Clinical Trial Sponsors, Contract Research Organizations (CROs), Hospitals, Academic Institutes and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 41: China 8-Year Perspective for ePRO, E-Patient Diaries and eCOA by End-Use - Percentage Breakdown of Value Revenues for Clinical Trial Sponsors, Contract Research Organizations (CROs), Hospitals, Academic Institutes and Other End-Uses for the Years 2023 & 2030
  • EUROPE
    • ePRO, E-Patient Diaries and eCOA Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
    • TABLE 42: Europe Recent Past, Current & Future Analysis for ePRO, E-Patient Diaries and eCOA by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 43: Europe 8-Year Perspective for ePRO, E-Patient Diaries and eCOA by Geographic Region - Percentage Breakdown of Value Revenues for France, Germany, Italy, UK and Rest of Europe Markets for Years 2023 & 2030
    • TABLE 44: Europe Recent Past, Current & Future Analysis for ePRO, E-Patient Diaries and eCOA by Solution Type - eClinical Outcome Assessments (eCOAs), ePatient Reported Outcomes (ePROs), Clinician Reported Outcomes (ClinROs), ePatient Diaries, Performance Outcomes (PerfOs) and Observer Reported Outcomes (ObsROs) - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 45: Europe 8-Year Perspective for ePRO, E-Patient Diaries and eCOA by Solution Type - Percentage Breakdown of Value Revenues for eClinical Outcome Assessments (eCOAs), ePatient Reported Outcomes (ePROs), Clinician Reported Outcomes (ClinROs), ePatient Diaries, Performance Outcomes (PerfOs) and Observer Reported Outcomes (ObsROs) for the Years 2023 & 2030
    • TABLE 46: Europe Recent Past, Current & Future Analysis for ePRO, E-Patient Diaries and eCOA by End-Use - Clinical Trial Sponsors, Contract Research Organizations (CROs), Hospitals, Academic Institutes and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 47: Europe 8-Year Perspective for ePRO, E-Patient Diaries and eCOA by End-Use - Percentage Breakdown of Value Revenues for Clinical Trial Sponsors, Contract Research Organizations (CROs), Hospitals, Academic Institutes and Other End-Uses for the Years 2023 & 2030
  • FRANCE
    • TABLE 48: France Recent Past, Current & Future Analysis for ePRO, E-Patient Diaries and eCOA by Solution Type - eClinical Outcome Assessments (eCOAs), ePatient Reported Outcomes (ePROs), Clinician Reported Outcomes (ClinROs), ePatient Diaries, Performance Outcomes (PerfOs) and Observer Reported Outcomes (ObsROs) - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 49: France 8-Year Perspective for ePRO, E-Patient Diaries and eCOA by Solution Type - Percentage Breakdown of Value Revenues for eClinical Outcome Assessments (eCOAs), ePatient Reported Outcomes (ePROs), Clinician Reported Outcomes (ClinROs), ePatient Diaries, Performance Outcomes (PerfOs) and Observer Reported Outcomes (ObsROs) for the Years 2023 & 2030
    • TABLE 50: France Recent Past, Current & Future Analysis for ePRO, E-Patient Diaries and eCOA by End-Use - Clinical Trial Sponsors, Contract Research Organizations (CROs), Hospitals, Academic Institutes and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 51: France 8-Year Perspective for ePRO, E-Patient Diaries and eCOA by End-Use - Percentage Breakdown of Value Revenues for Clinical Trial Sponsors, Contract Research Organizations (CROs), Hospitals, Academic Institutes and Other End-Uses for the Years 2023 & 2030
  • GERMANY
    • TABLE 52: Germany Recent Past, Current & Future Analysis for ePRO, E-Patient Diaries and eCOA by Solution Type - eClinical Outcome Assessments (eCOAs), ePatient Reported Outcomes (ePROs), Clinician Reported Outcomes (ClinROs), ePatient Diaries, Performance Outcomes (PerfOs) and Observer Reported Outcomes (ObsROs) - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 53: Germany 8-Year Perspective for ePRO, E-Patient Diaries and eCOA by Solution Type - Percentage Breakdown of Value Revenues for eClinical Outcome Assessments (eCOAs), ePatient Reported Outcomes (ePROs), Clinician Reported Outcomes (ClinROs), ePatient Diaries, Performance Outcomes (PerfOs) and Observer Reported Outcomes (ObsROs) for the Years 2023 & 2030
    • TABLE 54: Germany Recent Past, Current & Future Analysis for ePRO, E-Patient Diaries and eCOA by End-Use - Clinical Trial Sponsors, Contract Research Organizations (CROs), Hospitals, Academic Institutes and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 55: Germany 8-Year Perspective for ePRO, E-Patient Diaries and eCOA by End-Use - Percentage Breakdown of Value Revenues for Clinical Trial Sponsors, Contract Research Organizations (CROs), Hospitals, Academic Institutes and Other End-Uses for the Years 2023 & 2030
  • ITALY
    • TABLE 56: Italy Recent Past, Current & Future Analysis for ePRO, E-Patient Diaries and eCOA by Solution Type - eClinical Outcome Assessments (eCOAs), ePatient Reported Outcomes (ePROs), Clinician Reported Outcomes (ClinROs), ePatient Diaries, Performance Outcomes (PerfOs) and Observer Reported Outcomes (ObsROs) - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 57: Italy 8-Year Perspective for ePRO, E-Patient Diaries and eCOA by Solution Type - Percentage Breakdown of Value Revenues for eClinical Outcome Assessments (eCOAs), ePatient Reported Outcomes (ePROs), Clinician Reported Outcomes (ClinROs), ePatient Diaries, Performance Outcomes (PerfOs) and Observer Reported Outcomes (ObsROs) for the Years 2023 & 2030
    • TABLE 58: Italy Recent Past, Current & Future Analysis for ePRO, E-Patient Diaries and eCOA by End-Use - Clinical Trial Sponsors, Contract Research Organizations (CROs), Hospitals, Academic Institutes and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 59: Italy 8-Year Perspective for ePRO, E-Patient Diaries and eCOA by End-Use - Percentage Breakdown of Value Revenues for Clinical Trial Sponsors, Contract Research Organizations (CROs), Hospitals, Academic Institutes and Other End-Uses for the Years 2023 & 2030
  • UNITED KINGDOM
    • TABLE 60: UK Recent Past, Current & Future Analysis for ePRO, E-Patient Diaries and eCOA by Solution Type - eClinical Outcome Assessments (eCOAs), ePatient Reported Outcomes (ePROs), Clinician Reported Outcomes (ClinROs), ePatient Diaries, Performance Outcomes (PerfOs) and Observer Reported Outcomes (ObsROs) - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 61: UK 8-Year Perspective for ePRO, E-Patient Diaries and eCOA by Solution Type - Percentage Breakdown of Value Revenues for eClinical Outcome Assessments (eCOAs), ePatient Reported Outcomes (ePROs), Clinician Reported Outcomes (ClinROs), ePatient Diaries, Performance Outcomes (PerfOs) and Observer Reported Outcomes (ObsROs) for the Years 2023 & 2030
    • TABLE 62: UK Recent Past, Current & Future Analysis for ePRO, E-Patient Diaries and eCOA by End-Use - Clinical Trial Sponsors, Contract Research Organizations (CROs), Hospitals, Academic Institutes and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 63: UK 8-Year Perspective for ePRO, E-Patient Diaries and eCOA by End-Use - Percentage Breakdown of Value Revenues for Clinical Trial Sponsors, Contract Research Organizations (CROs), Hospitals, Academic Institutes and Other End-Uses for the Years 2023 & 2030
  • REST OF EUROPE
    • TABLE 64: Rest of Europe Recent Past, Current & Future Analysis for ePRO, E-Patient Diaries and eCOA by Solution Type - eClinical Outcome Assessments (eCOAs), ePatient Reported Outcomes (ePROs), Clinician Reported Outcomes (ClinROs), ePatient Diaries, Performance Outcomes (PerfOs) and Observer Reported Outcomes (ObsROs) - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 65: Rest of Europe 8-Year Perspective for ePRO, E-Patient Diaries and eCOA by Solution Type - Percentage Breakdown of Value Revenues for eClinical Outcome Assessments (eCOAs), ePatient Reported Outcomes (ePROs), Clinician Reported Outcomes (ClinROs), ePatient Diaries, Performance Outcomes (PerfOs) and Observer Reported Outcomes (ObsROs) for the Years 2023 & 2030
    • TABLE 66: Rest of Europe Recent Past, Current & Future Analysis for ePRO, E-Patient Diaries and eCOA by End-Use - Clinical Trial Sponsors, Contract Research Organizations (CROs), Hospitals, Academic Institutes and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 67: Rest of Europe 8-Year Perspective for ePRO, E-Patient Diaries and eCOA by End-Use - Percentage Breakdown of Value Revenues for Clinical Trial Sponsors, Contract Research Organizations (CROs), Hospitals, Academic Institutes and Other End-Uses for the Years 2023 & 2030
  • ASIA-PACIFIC
    • ePRO, E-Patient Diaries and eCOA Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
    • TABLE 68: Asia-Pacific Recent Past, Current & Future Analysis for ePRO, E-Patient Diaries and eCOA by Solution Type - eClinical Outcome Assessments (eCOAs), ePatient Reported Outcomes (ePROs), Clinician Reported Outcomes (ClinROs), ePatient Diaries, Performance Outcomes (PerfOs) and Observer Reported Outcomes (ObsROs) - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 69: Asia-Pacific 8-Year Perspective for ePRO, E-Patient Diaries and eCOA by Solution Type - Percentage Breakdown of Value Revenues for eClinical Outcome Assessments (eCOAs), ePatient Reported Outcomes (ePROs), Clinician Reported Outcomes (ClinROs), ePatient Diaries, Performance Outcomes (PerfOs) and Observer Reported Outcomes (ObsROs) for the Years 2023 & 2030
    • TABLE 70: Asia-Pacific Recent Past, Current & Future Analysis for ePRO, E-Patient Diaries and eCOA by End-Use - Clinical Trial Sponsors, Contract Research Organizations (CROs), Hospitals, Academic Institutes and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 71: Asia-Pacific 8-Year Perspective for ePRO, E-Patient Diaries and eCOA by End-Use - Percentage Breakdown of Value Revenues for Clinical Trial Sponsors, Contract Research Organizations (CROs), Hospitals, Academic Institutes and Other End-Uses for the Years 2023 & 2030
  • REST OF WORLD
    • TABLE 72: Rest of World Recent Past, Current & Future Analysis for ePRO, E-Patient Diaries and eCOA by Solution Type - eClinical Outcome Assessments (eCOAs), ePatient Reported Outcomes (ePROs), Clinician Reported Outcomes (ClinROs), ePatient Diaries, Performance Outcomes (PerfOs) and Observer Reported Outcomes (ObsROs) - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 73: Rest of World 8-Year Perspective for ePRO, E-Patient Diaries and eCOA by Solution Type - Percentage Breakdown of Value Revenues for eClinical Outcome Assessments (eCOAs), ePatient Reported Outcomes (ePROs), Clinician Reported Outcomes (ClinROs), ePatient Diaries, Performance Outcomes (PerfOs) and Observer Reported Outcomes (ObsROs) for the Years 2023 & 2030
    • TABLE 74: Rest of World Recent Past, Current & Future Analysis for ePRO, E-Patient Diaries and eCOA by End-Use - Clinical Trial Sponsors, Contract Research Organizations (CROs), Hospitals, Academic Institutes and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 75: Rest of World 8-Year Perspective for ePRO, E-Patient Diaries and eCOA by End-Use - Percentage Breakdown of Value Revenues for Clinical Trial Sponsors, Contract Research Organizations (CROs), Hospitals, Academic Institutes and Other End-Uses for the Years 2023 & 2030

IV. COMPETITION